Cxbladder® Detect
UC risk stratification in patients presenting with haematuria.
Cxbladder Detect is an established test, optimised for the risk stratification of urothelial cancer (UC) in patients presenting with haematuria.
Detect helps to de-intensify clinical work-up in those with a low probability Detect test result, improving practice workflow and efficiency in urological care, while giving patients the best experience possible.
• Enables reliable risk stratification in patients presenting with haematuria. Safely de-intensifies clinical workup in patients with a low probability Detect test result, while prioritising those who require immediate care.
• Spares patients with a low probability Detect test result the discomfort, anxiety and risks of an invasive procedure.
• A reliable adjunct when other tests are inconclusive. Resolves atypical cytology and equivocal cystoscopy.
Not for active urinary tract infection. Not a standalone replacement for cystoscopy in high-risk patients.
| Step / Test | Accuracy | Notes |
|---|---|---|
| Sensitivity | 82% | |
| NPV | 97% | |
| Specificity | 94% (when higher 0.23 cut point on test report is used) |
Urine in Cxbladder container
30–50 mL midstream urine collected into the Cxbladder collection tube (contains preservative). Do not use catheter samples.
- First void urine (Only 2nd pass of the day or later is accepted)
- Grossly bloody urine
- Acute UTI (Treat UTI first and delay test for 2 weeks)
- <2 weeks after cystoscopy
- <6 weeks after BCG
Available through Codex Genetics as the authorised Pacific Edge distributor in Hong Kong.
Cxbladder specimens must be collected using the dedicated Cxbladder collection kit.
- Request a collection kit from your healthcare provider or Codex Genetics.
- Collect midstream urine (30–50 mL) into the provided tube with preservative.
- Seal securely; store at room temperature.
- Deliver to Codex Genetics Laboratory within 5 days of collection. Address: Unit 220, 2/F, Building 16W, HKSTP, Pak Shek Kok, NT, Hong Kong.
Please contact us for pricing.
- Low/Negligible Risk Patients:
- Clinicians should obtain repeat urinalysis within six months rather than perform immediate cystoscopy or imaging
- Intermediate Risk Patients:
- Clinicians should recommend cystoscopy and renal ultrasound
- Clinicians may offer urine cytology or validated urine-based tumor markers to appropriately counseled patients to facilitate the decision regarding utility of cystoscopy; renal and bladder ultrasound should still be performed.
- If UBTM used to defer cystoscopy, repeat urinalysis within 1 year. Patients with persistent microhematuria should undergo cystoscopy
- High Risk Patients:
- Clinicians should perform cystoscopy and axial upper tract imaging
Microhaematuria is common in the general population and drives high cystoscopy volumes. The majority of microhaematuria cases are benign. Cxbladder Detect enables clinicians to identify low-risk patients who may not need invasive investigation, reducing patient anxiety and healthcare costs while maintaining safety.
Hong Kong-based molecular diagnostics laboratory specialising in clinical genomics, precision oncology, and rare disease diagnosis. Accredited to ISO 27001 and GenQA standards.
The services provided by Codex Genetics are for research use only, and they are not suitable for diagnostic and/or treatment use, unless otherwise instructed by licensed medical professionals.
除非有醫療專業人員另行指示，此網站的服務只供研究用途，並不供作診斷或治療任何疾病之用。
CoGenesis® is a trademark of Codex Genetics Limited
© 2026 Codex Genetics Limited. All rights reserved.
